StreetInsider.com News Articles

Theralase raises $1.1 million in private placement financing

Tue, 10 Mar 2026 07:02:12 -0400

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) completed a non-brokered private placement offering that raised CAD $1.1 million, the clinical stage pharmaceutical company announced.

The company issued 4,230,770 units at CAD $0.26 per unit. Each unit includes one common share and one warrant that allows the holder to purchase an additional share at CAD $0.36 for five years from the closing date.

Company insiders purchased 100,000 units for CAD $26,000 as part of the offering. The transaction qualifies as a related party transaction under Canadian securities regulations, though the company is exempt from formal valuation requirements and minority shareholder approval.

Theralase stated it

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Tue, 10 Mar 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units").

On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000.

Each Unit consisted of one common share of the Company ("Common Share")

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Tue, 10 Mar 2026 07:00:00 -0400

On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000.

Each Unit consisted of one common share of the Company ("Common Share")

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Mon, 09 Mar 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in the destruction of Muscle Invasive Bladder Cancer ("MIBC").

In the MIBC preclinical models conducted by the Theralase® research team, Rutherrin® demonstrated an ability to significantly enhance the efficacy of radiation therapy in the destruction of MIBC, supporting its potential as an effective drug for

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Mon, 09 Mar 2026 07:00:00 -0400

Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Mon, 02 Mar 2026 07:00:00 -0400

Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon

Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that recent in vitro data demonstrates an enhanced bladder cancer cell kill, when light-activated Ruvidar® is combined with recombinant human interferon alpha-2b ("rhIFNα2b" or "interferon").

In preclinical research, T24 human bladder cancer cells were treated with

Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Mon, 02 Mar 2026 07:00:00 -0400

Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon

In preclinical research, T24 human bladder cancer cells were treated with

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Fri, 20 Feb 2026 07:00:00 -0400

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.

Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress ("EAU26").

The EAU has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Fri, 20 Feb 2026 07:00:00 -0400

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress ("EAU26").
The EAU has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Tue, 17 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress ("EAU26").
The EAU has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ" for presentation at EAU26 to be held

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Tue, 17 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Congress ("EAU26").
The EAU has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ" for presentation at EAU26 to be held

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Tue, 10 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the American Urological Association ("AUA") Annual Meeting.
The program committee of the AUA has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ" for an interactive poster presentation at

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Tue, 10 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the American Urological Association ("AUA") Annual Meeting.
The program committee of the AUA has accepted Theralase®'s abstract titled, "Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ" for an interactive poster presentation at

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Wed, 04 Feb 2026 07:00:00 -0400

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer.
To date, 90 patients have been enrolled and treated with the Theralase® Study Procedure, achieving the patient enrollment specified by

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Wed, 04 Feb 2026 07:00:00 -0400

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer.
To date, 90 patients have been enrolled and treated with the Theralase® Study Procedure, achieving the patient enrollment specified by

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Mon, 02 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully completed its targeted milestone of enrolling and treating 90 patients in a multi-center Phase II clinical study for bladder cancer.
The Phase II clinical study has a primary endpoint of efficacy, a secondary endpoint of duration of response and a

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Mon, 02 Feb 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully completed its targeted milestone of enrolling and treating 90 patients in a multi-center Phase II clinical study for bladder cancer.
The Phase II clinical study has a primary endpoint of efficacy, a secondary endpoint of duration of response and a

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Mon, 12 Jan 2026 07:00:00 -0400

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar^® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1).
Combination therapy aims to offer a complementary approach that may provide additional treatment options for patients with NMIBC.
Collaboration reflects the shared commitment of Ferring and Theralase® to advance treatment options for NMIBC patients.
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Ferring Pharmaceuticals and Theralase^® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) are pleased to announce that they have entered into a collaborative

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Mon, 12 Jan 2026 07:00:00 -0400

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar^® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1).
Combination therapy aims to offer a complementary approach that may provide additional treatment options for patients with NMIBC.
Collaboration reflects the shared commitment of Ferring and Theralase® to advance treatment options for NMIBC patients.
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Ferring Pharmaceuticals and Theralase^® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) are pleased to announce that they have entered into a collaborative

Theralase raises $1.3M in private placement for cancer study

Tue, 23 Dec 2025 16:42:10 -0400

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) closed a non-brokered private placement raising approximately $1.33 million, the clinical-stage pharmaceutical company announced.

The company issued 7,850,882 units at $0.17 per unit. Each unit consists of one common share and one warrant allowing the purchase of an additional share at $0.21 within five years.

Theralase plans to use proceeds to advance its Phase II non-muscle invasive bladder cancer clinical study, along with working capital and general corporate purposes.

The company paid $31,658 in finder's fees, with $15,470 in cash and $16,188 through 95,221 common shares. An additional 186,221 non-transferable finder warrants were issued, exercisable at

Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Tue, 23 Dec 2025 16:40:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units").
On closing, the Corporation issued an aggregate of 7,850,882 Units at a price of $CAN 0.17 per Unit for aggregate gross proceeds of approximately $CAN 1,334,650.
Each Unit consists of one common share of the Company ("Common Share") and one common share purchase warrant ("Warrant"). Each

Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Tue, 23 Dec 2025 16:40:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units").
On closing, the Corporation issued an aggregate of 7,850,882 Units at a price of $CAN 0.17 per Unit for aggregate gross proceeds of approximately $CAN 1,334,650.
Each Unit consists of one common share of the Company ("Common Share") and one common share purchase warrant ("Warrant"). Each

Theralase launches $2 million private placement, ends brokered financing

Fri, 12 Dec 2025 17:02:13 -0400

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) commenced a non-brokered private placement to raise up to CAD $2 million and terminated its previously announced brokered financing with Research Capital Corporation.

The Toronto-based clinical stage pharmaceutical company will sell units priced at CAD $0.17 each. Each unit consists of one common share and one warrant that allows the holder to purchase an additional common share at CAD $0.21 for 60 months after closing.

The company plans to use proceeds to advance its Phase II Non-Muscle Invasive Bladder Cancer clinical study and for working capital needs. The offering is scheduled to close during the

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Fri, 12 Dec 2025 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 ("Offering").
In the Offering, each Unit is priced at $CAN 0.17 and consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company ("Warrant Share")

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Fri, 12 Dec 2025 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 ("Offering").
In the Offering, each Unit is priced at $CAN 0.17 and consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company ("Warrant Share")